<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26031713</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>02</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>02</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-1101</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>31</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2016</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical apheresis</Title>
<ISOAbbreviation>J Clin Apher</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation.</ArticleTitle>
<Pagination>
<MedlinePgn>347-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jca.21404</ELocationID>
<Abstract>
<AbstractText>Extracorporeal photopheresis (ECP) is a commonly used treatment for severe graft-versus-host-disease (GVHD). We sought to evaluate the effects of ECP over a prolonged period on forced expiratory volume in 1 s (FEV1) in patients with pulmonary GVHD. We identified eight patients who developed new airflow obstruction following allogeneic stem cell transplantation and a substantial decline in FEV1 despite receiving corticosteroids and standard therapy for pulmonary GVHD. Those eight patients were treated with ECP for a period of 1 year, with a primary endpoint of FEV1 change during this treatment period. Over the first 3 months of ECP, there was no further decline in FEV1 in seven of the eight patients. However, over the 1 year period, only two of the eight patients had stability in FEV1. The rate of FEV1 decline was substantially less once ECP was initiated, though the median FEV1 continued to decline over 1 year of therapy. All patients survived through the first year of ECP therapy. There was a significant decrease in the median dose of prednisone per patient throughout the 12 months of ECP treatment. ECP shows promise in slowing rate of decline of FEV1 in pulmonary GVHD, though the effects may not be long lived. J. Clin. Apheresis 31:347-352, 2016. © 2015 Wiley Periodicals, Inc. </AbstractText>
<CopyrightInformation>© 2015 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brownback</LastName>
<ForeName>Kyle R</ForeName>
<Initials>KR</Initials>
<AffiliationInfo>
<Affiliation>Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simpson</LastName>
<ForeName>Steven Q</ForeName>
<Initials>SQ</Initials>
<AffiliationInfo>
<Affiliation>Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pitts</LastName>
<ForeName>Lucas R</ForeName>
<Initials>LR</Initials>
<AffiliationInfo>
<Affiliation>Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Polineni</LastName>
<ForeName>Deepika</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McGuirk</LastName>
<ForeName>Joseph P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ganguly</LastName>
<ForeName>Siddhartha</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aljitawi</LastName>
<ForeName>Omar S</ForeName>
<Initials>OS</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Tara L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Anurag</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abhyankar</LastName>
<ForeName>Sunil</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>05</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Apher</MedlineTA>
<NlmUniqueID>8216305</NlmUniqueID>
<ISSNLinking>0733-2459</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001989">Bronchiolitis Obliterans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005541">Forced Expiratory Volume</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008171">Lung Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017893">Photopheresis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012129">Respiratory Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">bronchiolitis obliterans syndrome</Keyword>
<Keyword MajorTopicYN="N">extracorporeal photopheresis</Keyword>
<Keyword MajorTopicYN="N">graft-versus-host-disease</Keyword>
<Keyword MajorTopicYN="N">pulmonary function testing</Keyword>
<Keyword MajorTopicYN="N">stem cell transplantation</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>02</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2015</Year>
<Month>04</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>04</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26031713</ArticleId>
<ArticleId IdType="doi">10.1002/jca.21404</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>